Q-omics provides the consensus-scored KCNJ6 profile across patient tissues and cancer cell-line models. KCNJ6 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, KCNJ6 is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, KCNJ6 RNA expression shows 11,612 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, HNSC, and TGCT as cancer lineages where KCNJ6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KCNJ6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KCNJ6 survival associations across molecular data types. KCNJ6 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (3) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KCNJ6 RNA expression–survival associations across cancer types. High KCNJ6 expression shows unfavorable associations in KIRC, UVM, ACC, KIRP, MESO and BLCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for KCNJ6 RNA expression.
This table summarizes KCNJ6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for KCNJ6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KCNJ6 shows lower tumor expression in KIRC and KICH and higher tumor expression in HNSC, BRCA, LUAD and LIHC. The HNSC box plot shows higher KCNJ6 RNA expression in tumor versus normal tissue (log2 FC = +0.065, t-test p < 0.001).
This table shows molecular features associated with KCNJ6 in patient tissues and cancer cell lines. In patient samples, KCNJ6 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, KCNJ6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and SOFT_TISSUE.
